Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: A systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis

Current Medical Research and Opinion

Volumn 29, Issue 11, 2013, Pages 1539-1551

  Compalati, Enrico ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergic rhinitis; Antihistamine; Meta analysis; Rhino conjunctivitis; Rupatadine; Systematic review

Indexed keywords

ALLERGEN; PLACEBO; RUPATADINE;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ASTHENIA; BACKACHE; DATA SYNTHESIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMBASE; EPIPHORA; EYE INFLAMMATION; FATIGUE; FOLLOW UP; HAY FEVER; HUMAN; INTERNAL VALIDITY; MEDLINE; NASAL PRURITUS; NOSE AIRFLOW; NOSE OBSTRUCTION; NOSE PROVOCATION TEST; PERENNIAL RHINITIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SNEEZING; SOMNOLENCE; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ANALOG SCALE;

CONJUNCTIVITIS, ALLERGIC; CYPROHEPTADINE; HISTAMINE ANTAGONISTS; HUMANS; PLATELET ACTIVATING FACTOR; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; URTICARIA;

EID: 84885696455     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.822855     Document Type: Review

References (52)

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2-8
2. Katelaris CH, Lee BW, Potter PC, et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy 2012;42:186-207
3. Bousquet J, Schü nemann HJ, Samolinski B, et al; World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130:1049-62
4. Rosenwasser LJ. Current understanding of the pathophysiology of allergic rhinitis. Immunol Allergy Clin North Am 2011;31:433-9
5. Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy 2012;26:187-90
6. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128:1139-50
7. Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000;55:17-27
8. Izquierdo I, Merlos M, Garća-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003;39:451-68 (Pubitemid 37039398)
9. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997;280:114-21 (Pubitemid 27171394)
10. Akagi M, Kanoh R, Fukuishi N, et al. Contribution of platelet activating factor (PAF) in histamine-induced model of nasal allergy in rats. Arerugi 1995;44:182-8
11. Tedeschi A, Milazzo N, Miadonna A. Nasal eosinophilia induced by PAFacether is accompanied by the release of eosinophil cationic protein. Eur Respir J 1994;7:1445-51 (Pubitemid 24268331)
12. Klementsson H, Andersson M. Eosinophil chemotactic activity of topical PAF on the human nasal mucosa. Eur J Clin Pharmacol 1992;42:295-9
13. Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008;63:5-28 (Pubitemid 351389146)
14. Metz M, Maurer M. Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Rev Clin Immunol 2011;7:15-20
15. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6
16. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31:150-3 (Pubitemid 34284917)
17. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. 2008. Available at: http://www.cochrane.org/ training/cochrane-handbook [last acessed 25 Jul 2013]
18. DigitizeIt 1.5.7 program. Braunschweig: Bormann, 2003
19. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-7 (Pubitemid 27517188)
20. Deeks JJ, Altman D, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care. London: BMJ, 2001:285-312
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60
22. Analyses Version 5.0 for Windows. Oxford: The Cochrane Collaboration, 2008
23. Marmouz F, Giralt J, Izquierdo I. Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial. J Asthma Allergy 2011;4:27-35
24. Valero A, Serrano C, Bartrá J, et al. Reduction of nasal volume after allergeninduced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. J Investig Allergol Clin Immunol 2009;19:488-93
25. Fantin S, Maspero J, Bisbal C, et al; international rupatadine study group. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 2008;63:924-31 (Pubitemid 351832790)
26. Stuebner P, Horak F, Zieglmayer R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006;96:37-44 (Pubitemid 43152666)
27. Guadañ o EM, Serra-Batlles J, Meseguer J, et al; Rupatadine Study Group. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004;59:766-71 (Pubitemid 38850353)
28. Molina M, Pinto E, Cisteró A, et al. Rupatadine 10 mg in adolescent and adult symptom relief of perennial allergic rhinitis. Therapy 2010;7:429-36
29. Kowalski M, Jurkiewicz D, Kruszewski J, et al. Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: a randomized, double-blind, controlled trial with loratadine and placebo. Therapy 2009;6:417-25
30. Izquierdo I, Pareds I, Lurigados C, et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy 2000;55:275
31. Potter P, Maspero J, Vermeulen J, et al. Allergy 2011;66:23
32. Lukat KF, Rivas P, Roger A, et al.; investigators working group clinical trial. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhino-conjunctivitis: a randomised, double-blind, placebocontrolled study. J Asthma Allergy 2013;6:31-9
33. Mart́nez-Có cera C, De Molina M, Mart́-Guadañ o E, et al; Spanish Rupatadine Rhinitis Study Group. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Investig Allergol Clin Immunol 2005;15:22-9
34. Saint-Martin F, Dumur JP, Pé rez I, et al; French Rupatadine-Rhinitis Study Group. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptorspecific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004;14:34-40 (Pubitemid 38506429)
35. Mion O, Mello J, Castro F, et al. Rupatadine fumarate is effective in the treatment of persistent allergic rhinitis: a multicentre study. Allergy 2007;62:137, meeting abstract 361
36. Canonica GW, Fumagalli F. Rupatadine 10mg versus placebo on inflammatory parameters after allergen challenge in patients with persistent allergic rhinitis (PER). Allergy 2008;63:204, meeting abstract 522
37. Valero A, Bartra J, Serrano C, et al. Rupatadine reduces nasal obstruction in allergen-induced rhinitis. Allergy 2007;62:137, meeting abstract 362
38. Rivas P, Mesa M, Valero A, et al. Moderate-severe persistent allergic rhinitis: long-term safety treatment with rupatadine. XVIII IFOS World Congress. Rome, Italy: 25-30 June 2005. Abstract G58
39. Arnaiz E, Izquiierdo I, Leuratti C, et al. Rupatadine reduces nasal and nonnasal symptoms in patients with seasonal allergic rhinitis exposed to allergen in the Vienna Challenge Chamber. XXIII Congress of the European Academy of Allergology and Clinical Immunology (EAACI). Amsterdam, The Netherlands: 12-16 June, 2004. Abstract 272
40. Rothstein, H. R., Sutton, A. J. and Borenstein, M. Publication Bias in Meta-Analysis, in Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments (eds H. R. Rothstein, A. J. Sutton and M. Borenstein), John Wiley & Sons, Ltd, Chichester, UK. 2006. doi: 10.1002/0470870168.ch1
41. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63 (Pubitemid 30422636)
42. Egger M, Smith GD, O'rourke K. Systematic Reviews in Healthcare. Metaanalysis in Context. London: BMJ Publishing Group, 1995
43. Moher D, Liberati A, Tetzlaff J, et al. The PRISMA statement Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097. doi:10.1371/journal.pmed. 1000097
44. Sackett DL, Rosenberg WMC, Gray JAM. Evidence-Based Medicine: What it is and what it isn't. BMJ 1996;312:71-2
45. Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy 2000;55:53-61 (Pubitemid 30314015)
46. Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine-and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010;163:1330-2
47. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. New Jersey: Lawrence Erlbaum, 1988
48. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;23;340:c332
49. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012;11:MR000030
50. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6 (Pubitemid 351632017)
51. Easterbrook PJ, Berlin J, Gopalan R, et al. Publication bias in clinical research. Lancet 1991;337:867-72
52. Valero A, Izquierdo I, Giralt J, et al. Rupatadine improves nasal symptoms, quality of life (ESPRINT-15) and severity in a subanalysis of a cohort of Spanish allergic rhinitis patients. J Investig Allergol Clin Immunol 2011;21:229-35